143 related articles for article (PubMed ID: 32286270)
1. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.
Sidana S; Milani P; Binder M; Basset M; Tandon N; Foli A; Dispenzieri A; Gertz MA; Hayman SR; Buadi FK; Lacy MQ; Kapoor P; Leung N; Rajkumar SV; Merlini G; Palladini G; Kumar SK
Blood Cancer J; 2020 Apr; 10(4):41. PubMed ID: 32286270
[TBL] [Abstract][Full Text] [Related]
2. Validation of the composite organ and hematologic response model for prognostic prediction in a Chinese light chain amyloidosis cohort.
Shen KN; Miao HL; Zhang L; Feng J; Cao XX; Li J
Leuk Lymphoma; 2021 Aug; 62(8):1892-1896. PubMed ID: 33602009
[TBL] [Abstract][Full Text] [Related]
3. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
4. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
6. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.
Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M
Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916
[TBL] [Abstract][Full Text] [Related]
7. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
8. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.
Minnema MC; Nasserinejad K; Hazenberg B; Hegenbart U; Vlummens P; Ypma PF; Kröger N; Wu KL; Kersten MJ; Schaafsma MR; Croockewit S; de Waal E; Zweegman S; Tick L; Broijl A; Koene H; Bos G; Sonneveld P; Schönland S
Haematologica; 2019 Nov; 104(11):2274-2282. PubMed ID: 30923094
[TBL] [Abstract][Full Text] [Related]
10. Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.
Kastritis E; Misra A; Gurskyte L; Kroi F; Verhoek A; Vermeulen J; Ammann E; Lam A; Cote S; Wechalekar AD
Hematology; 2023 Dec; 28(1):2157581. PubMed ID: 36607151
[TBL] [Abstract][Full Text] [Related]
11. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
[TBL] [Abstract][Full Text] [Related]
12. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
14. Characterization and prognostic implication of delayed complete response in AL amyloidosis.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Lisa Hwa Y; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Vincent Rajkumar S; Kyle RA; Dispenzieri A
Eur J Haematol; 2021 Mar; 106(3):354-361. PubMed ID: 33230879
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
[TBL] [Abstract][Full Text] [Related]
16. Deferred autologous stem cell transplantation in systemic AL amyloidosis.
Manwani R; Hegenbart U; Mahmood S; Sachchithanantham S; Kyriakou C; Yong K; Popat R; Rabin N; Whelan C; Dittrich T; Kimmich C; Hawkins P; Schönland S; Wechalekar A
Blood Cancer J; 2018 Nov; 8(11):101. PubMed ID: 30397193
[TBL] [Abstract][Full Text] [Related]
17. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
[TBL] [Abstract][Full Text] [Related]
18. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
19. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.
Sidiqi MH; Aljama MA; Buadi FK; Warsame RM; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Hogan WJ; Gertz MA
J Clin Oncol; 2018 May; 36(13):1323-1329. PubMed ID: 29558277
[TBL] [Abstract][Full Text] [Related]
20. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]